Clinical trials: Intermediate Risk Prostate Cancer
Prostate Cancer
Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcer
This is a prospective, open, randomized phase II trial.
- Trial name
- STUNNIN (NCT05557604)
- Testing
- Decapeptyl
- Where
- 3 sites in Italy
- Volunteers
- 146 people
- Sponsor
- Regina Elena Cancer Institute
HIGH RISK PROSTATE CANCER
Stereotactic Pelvic Brachytherapy With HDR Boost for Dose Escalation in High Tier Intermediate and High Risk Prostate ca
HDR brachytherapy in conjunction with pelvic SABR in high tier intermediate and high risk prostate cancer patients can provide a safe and effective means of radiotherapy dose escalation.
- Trial name
- SPARE (NCT04236752)
- Testing
- Stereotactic Ablative Body Radiation (SBRT)
- Where
- Canada
- Volunteers
- 33 people
- Sponsor
- Sunnybrook Health Sciences Centre
Prostate Cancer
LDR vs. HDR Brachytherapy for Prostate Cancer
H17-02904 is a randomized comparison of low dose rate vs. high dose rate prostate brachytherapy for favorable and intermediate risk prostate cancer suitable for brachytherapy as monotherapy.
- Trial name
- LDR/HDRmono (NCT03426748)
- Testing
- Low dose rate prostate brachytherapy, High dose rate prostate brachytherapy
- Where
- Canada
- Volunteers
- 140 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer, Laser
Focal Laser Ablation in Prostate Cancer
To assess the effectiveness of MRI-US or PSMA PET/CT-U/S fusion-guided focal laser ablation (FLA) for the treatment of a localized, intermediate-risk prostate cancer in terms of short-term oncological \& functional outcomes.
- Trial name
- NCT06916013
- Testing
- Focal laser ablation
- Volunteers
- 30 people
- Sponsor
- Ain Shams University
Prostate Cancer
Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer
The purpose of this study is to determine the clinical efficacy and toxicity of High-dose rate (HDR) brachytherapy as monotherapy for the treatment of low risk and intermediate risk prostate cancer.
- Trial name
- NCT02077335
- Testing
- HDR brachytherapy monotherapy
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- CSSS de Gatineau
Intermediate-risk Prostate Cancer, High-risk Prostate Cancer
COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P)
This retrospective, multicentre comparative analysis aims to evaluate a new staging method for i) improved detection of intraprostatic index lesions, ii) local T-staging and iii) lymph node (LN) staging in men with clinically…
- Trial name
- COMBINE-P (NCT07455097)
- Testing
- PSMA-11
- Where
- 10 sites in Austria, Belgium and 5 more
- Volunteers
- 600 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Prostate Cancer, Prostate Cancer (Adenocarcinoma)
ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0
Published clinical evidence confirms that a single dose of 24 Gy provides unprecedented long-term local control in primary and metastatic prostate cancer with safe toxicity profiles, provided that exposure of surrounding healthy…
- Conditions
- Prostate Cancer, Prostate Cancer (Adenocarcinoma), Prostate Cancer Non-Metastatic
- Trial name
- ABRUPT 2 (NCT07407608)
- Testing
- SBRT, SDRT
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- University of Milano Bicocca
Prostate Cancer
External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer
Primary Objective: To assess the possible improvement in prostate specific antigen (PSA) outcome of short course androgen suppression therapy in conjunction with dose-escalation intensity modulated radiation therapy (IMRT), 3D…
- Trial name
- NCT00388804
- Testing
- Radiation Therapy, Bicalutamide, Leuprolide
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer Of Prostate
A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy
Background: Prostate cancer is often treated with radiation and ADT (ADT is androgen deprivation therapy). Up to 30% of these cancers recur within 5 years of treatment.
- Trial name
- NCT05361798
- Testing
- PDS01ADC, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients
The investigators are imaging patients with prostate cancer using a new PET imaging agent (Ga-68-PSMA-11) in order to evaluate it's ability to detection prostate cancer in patients with high risk disease prior to prostatectomy.
- Trial name
- PSMA PreRP (NCT02919111)
- Testing
- Ga-68 labeled PSMA-11 PET
- Where
- United States
- Volunteers
- 299 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Internal Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. PURPOSE: This clinical trial is studying the side effects and how well internal radiation therapy works in…
- Trial name
- NCT00573833
- Testing
- questionnaire administration, quality-of-life assessment, brachytherapy
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Hypofractionated SBRT For Prostate Cancer
The purpose of this study is to determine, in both low-risk and intermediate-risk cohorts, the rates of acute and late grade 3 or higher gastrointestinal and genitourinary toxicity observed during a 24 month follow up and to…
- Trial name
- NCT00977860
- Testing
- Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 163 people
- Sponsor
- Adam Olson
Prostate Cancer
SpaceIT Hydrogel System for Perirectal Spacing
To evaluate the safety and effectiveness of the SpaceIT™ Hydrogel System in patients undergoing External Beam Radiotherapy (EBRT) for the treatment of prostate cancer.
- Trial name
- HYDROSPACE (NCT06451614)
- Testing
- SpaceIT Hydrogel System, Commercially available Boston Scientific Spacer
- Where
- 26 sites in United States, Canada
- Volunteers
- 230 people
- Sponsor
- Boston Scientific Corporation
Prostate Cancer, Neoadjuvant Therapy
Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy
RATIONALE: Neoadjuvant hormonal therapy using luteinizing hormone releasing hormone (LHRH) agonists and/or anti-androgens has already demonstrated to downstage primary prostate cancer in patients treated by radical prostatectomy…
- Conditions
- Prostate Cancer, Neoadjuvant Therapy, Androgen Antagonists, Prostatectomy
- Trial name
- ARNEO (NCT03080116)
- Testing
- ARN-509, Degarelix
- Where
- Belgium
- Volunteers
- 90 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Prostate Cancer
Continued Access of Focal MR-Guided Focused Ultrasound for Localized Intermediate Risk Prostate Lesions
This extended clinical investigation is a multicenter, prospective, single arm study intended to provide continued access of the Exablate Model 2100 device (Exablate Prostate) to patients for treatment of prostate lesions and…
- Trial name
- NCT03998657
- Testing
- Exablate Prostate Treatment
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- InSightec
Prostate Cancer
COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer
A Randomized Trial of Neoadjuvant Leuprorelin, Darolutamide or Both Prior to Radical Prostatectomy for Intermediate or High-risk Prostate Cancer.
- Trial name
- COAction (NCT06627530)
- Testing
- Darolutamide Oral Tablet, leuprorelin
- Where
- 6 sites in Brazil
- Volunteers
- 144 people
- Sponsor
- Brazilian Clinical Research Institute
Prostate Cancer
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
The primary objectives of this study are to evaluate the safety and tolerability of xaluritamig administered as monotherapy or in combination with an oral Gonadotropin-releasing Hormone (GnRH) antagonist in the neoadjuvant…
- Trial name
- NCT06613100
- Testing
- Xaluritamig, GnRH Antagonist
- Where
- 9 sites in United States, Germany
- Volunteers
- 40 people
- Sponsor
- Amgen
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery
This phase 2-3 trial studies the utility of 68-gallium (68Ga)-prostate-specific membrane antigen 11 (PSMA-11) positron emission tomography/magnetic resonance imaging (PET/MRI) to find tumors in patients with prostate cancer who…
- Trial name
- NCT02678351
- Testing
- 68Ga-PSMA-11, Magnetic resonance imaging (MRI), Positron Emission Tomography (PET)
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Andrei Iagaru
Prostate Cancer
Cost-utility of Focal HIFU vs Prostatectomy
Medico-Economic Randomized Trial comparing Focal HIFU Treatment to Radical Prostatectomy in Patients with Favorable Intermediate Risk Prostate Cancer
- Trial name
- EMERHIT (NCT05710861)
- Testing
- F-HIFU, Radical Prostatectomy
- Where
- 20 sites in France, Guadeloupe
- Volunteers
- 346 people
- Sponsor
- University Hospital, Bordeaux
Prostate Cancer, Prostatic Neoplasm
Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly Diagnosed
This is a diagnostic accuracy prospective, single-centre, open-label, single group assignment interventional study. Its aim is to evaluate the diagnostic accuracy of [68Ga]Ga-PSMA-11 PET/CT in detection of primary tumour and…
- Conditions
- Prostate Cancer, Prostatic Neoplasm, Urogenital Neoplasms, Prostatic Disease
- Trial name
- PSMA-PROSTAPET (NCT04462926)
- Testing
- [68Ga]Ga-PSMA-11 PET/CT
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena